Welcome to our dedicated page for CRH Public Company news (Ticker: $CRH), a resource for investors and traders seeking the latest updates and insights on CRH Public Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRH Public Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRH Public Company's position in the market.
CRH PLC announced the filing of Form 10-Q for the quarter ended March 31, 2024, with the SEC. The form is available on the SEC and company websites. Contact Neil Colgan for enquiries.
CRH plc has completed the latest phase of its share buyback program, returning $0.3 billion to shareholders. Since May 2018, $7.6 billion has been returned to shareholders. HSBC Securities (USA) Inc. will repurchase ordinary shares for up to $0.3 billion on behalf of CRH, starting on May 10, 2024. The Buyback aims to reduce CRH's share capital and will be conducted in compliance with relevant regulations.
CRH plc reported Q1 2024 results with total revenues of $6.5bn (+2%), net income of $114m, and adjusted EBITDA of $445m (+15%). The company completed acquisitions worth $2.2bn and divestitures of $0.7bn. CRH reaffirmed FY24 guidance with net income ranging from $3.55bn to $3.80bn.